On August 28, 2025 Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, reported that management is scheduled to participate in three investor conferences in September (Press release, Kura Oncology, AUG 28, 2025, View Source [SID1234655550]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Cantor Global Health Conference
Thursday, September 4, 2025
8:35 a.m. ET / 5:35 a.m. PT

H.C. Wainwright 27th Annual Global Investment Conference
Monday, September 8, 2025
1:00 p.m. ET / 10:00 a.m. PT

Morgan Stanley 23rd Annual Global Healthcare Conference
Wednesday, September 10, 2025
1:50 p.m. ET / 10:50 a.m. PT

Live audio webcasts will be available in the Investors section of Kura’s website at View Source, with archived replays available following all three events.

On August 28, 2025 Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in predictive computational target discovery powered by AI/ML, reported that management will participate in a fireside chat at the H.C. Wainwright 27th Annual Global Investment Conference (Press release, Compugen, AUG 28, 2025, https://www.prnewswire.com/news-releases/compugen-to-present-at-the-hc-wainwright-27th-annual-global-investment-conference-302540915.html [SID1234655564]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The fireside chat will be available on demand on the Investor Relations section of Compugen’s website at www.cgen.com from Friday, September 5, 2025, 7:00 AM ET for 90 days.

On August 28, 2025 Alector, Inc. (Nasdaq: ALEC), a late-stage clinical biotechnology company focused on developing therapies to counteract the devastating progression of neurodegeneration, reported that management will participate in the following upcoming investor conferences (Press release, Alector, AUG 28, 2025, View Source [SID1234655541]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Cantor Global Healthcare Conference 2025 (New York, New York)
Thursday, September 4, 2025, at 3:55 p.m. ET, fireside chat
Morgan Stanley 23rd Annual Global Healthcare Conference (New York, New York)
Monday, September 8, 2025, at 10:00 a.m. ET, fireside chat
H.C. Wainwright 27th Annual Global Investment Conference (New York, New York)
Tuesday, September 9, 2025, at 1:30 p.m. ET, company presentation

A webcast of each conference presentation will be available on the "Events & Presentations" page within the Investors section of the Alector website at View Source Replays of the webcasts will be available on the Alector website for 90 days following the presentation dates.

On August 28, 2025 Merck (NYSE: MRK), known as MSD outside of the United States and Canada, reported that Caroline Litchfield, executive vice president and chief financial officer, and Eliav Barr, senior vice president, head of global clinical development and chief medical officer, Merck Research Laboratories, are scheduled to participate in a fireside chat at the 2025 Wells Fargo Healthcare Conference on Thursday, Sept. 4, 2025, at 11:50 a.m. EDT (Press release, Merck & Co, AUG 28, 2025, View Source [SID1234655551]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Investors, analysts, members of the media and the general public are invited to listen to a live audio webcast of the presentation at this weblink.

On August 28, 2025 Foresee Pharmaceuticals (6576.TWO), ("Foresee") reported that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application (NDA) for CAMCEVI ETM (leuprolide mesylate 21 mg, ready-to-use long-acting injectable (LAI) formulation administered every 3 months), as a treatment for advanced prostate cancer (Press release, Foresee Pharmaceuticals, AUG 28, 2025, View Source [SID1234655565]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"The approval of CAMCEVI ETM (21 mg) is a significant step toward our mission in improving the standard of care and the lives of patients," said Dr. Ben Chien, founder, Chairman, and CEO of Foresee. "It is also a key step in our efforts to build Foresee as a profitable and growing business. We want to thank the team and all stakeholders for their tireless work, which has made this approval possible.

The FDA approval was based on the successful Phase 3 clinical study with a total of 144 advanced prostate cancer patients enrolled, in which treatment with CAMCEVI ETM was demonstrated to be effective, safe, and well tolerated, with 97.9% of the subjects achieving the primary efficacy endpoint.

As it was the case for CAMCEVI 42 mg, we anticipate the commercial launch to take place after obtaining a J-code. The commercial market access strategy established by our partner will seek to find a balance between near term uptake and the optimization of mid/long term growth.

CAMCEVI ETM is exclusively licensed to Accord BioPharma, Inc., the U.S. specialty division of Intas Pharmaceuticals, Ltd. for commercialization in the U.S.